Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses

Table 3 Survival (PFS, OS) by Quality of Response to Romidepsin

	Objective responders	CR/CRu	CR/CRu	PR	SD90	SD < 90/ PD/NE
		≥ 12 months	< 12 months
	(CR/CRu + PR; n = 33)	(n = 10)	(n = 9)	(n = 14)	(n = 23)	(n = 74)
Median OS, months (range)	30	NR	NR	18	NR	5
Median OS, months (range)	(2.0-49.5)	(21.2-49.5)	(9.2-32.0)	(2.0-38.8)	(8.1-44.6)	(0.3-29.3)
Median PFS, months, (range)	20	29	13	7	7	2
Median PFS, months, (range)	(1.6-49.8)	(17.6-49.8)	(1.6-26.0)	(1.9-18.1)	(3.3-37.7)	(0.3-14.4)

Abbreviations: CR/CRu confirmed/unconfirmed complete response, NR not reached, OS overall survival, PD progressive disease, PFS progression-free survival, PR partial response, SD stable disease, SD90 SD ≥ 90 days.

ISSN: 1756-8722